Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods.
Phase 4
Completed
- Conditions
- Chronic Renal Insufficiency.
- Registration Number
- RPCEC00000082
- Lead Sponsor
- Center of Molecular Immunology(CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 621
Inclusion Criteria
1.Patients with inform consent signed. 2.Patients with stable dialysis treatment at least of 3 months prior. 3.Patients who are receiving ior EPOCIM for the treatment of anemia associated with CRF. 4.Age less than 18 years. 5.To be included in the study patients of both sexes.
Exclusion Criteria
1.Patients with known hypersensitivity to products derived from cells above or hypersensitivity to human albumin. 2.Patients pregnant or breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method